10-Q quarterly report · filed Nov 13, 2026

TuHURA Biosciences, Inc./NV (HURA) Q3 2026 10-Q Quarterly Report

Short answer

TuHURA Biosciences, Inc./NV (HURA) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$6M
+9.8% YoY · +30.5% QoQ
EPS (diluted)
−$0.10
+28.6% YoY · +28.6% QoQ

Source: XBRL data from the TuHURA Biosciences, Inc./NV (HURA) Q3 2026 10-Q on SEC EDGAR. USD.

TuHURA Biosciences, Inc./NV Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no products approved for sale
  • Net loss $6.4M vs $7.1M YoY, operating loss $5.7M vs $6.7M
  • Best program TBS-2025 R&D $0.4M, up $0.1M; IFx-2.0 $1.1M, down $0.5M
  • Cash $1.9M; operating cash use $18.1M, financing cash provided $16.5M
  • Runway into 2028 projected; additional funding needed, with clinical and development costs expected to increase substantially

Risk Factors

  • No material changes to previously disclosed risk factors since the 2025 Form 10-K
  • No newly added risk factor identified this quarter
  • Carried-forward risks remain those disclosed in the 2025 Form 10-K and March 31, 2026 Form 10-Q

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other TuHURA Biosciences, Inc./NV quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.